Commonwealth Equity Services’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$24.5M Buy
54,972
+829
+2% +$387K 0.03% 494
2025
Q4
$24.5M Sell
54,143
-4,142
-7% -$1.79M 0.03% 494
2025
Q3
$22.8M Sell
58,285
-1,113
-2% -$465K 0.03% 515
2025
Q2
$26.4M Sell
59,398
-6,346
-10% -$2.92M 0.03% 482
2025
Q1
$31.9M Buy
65,744
+1,624
+3% +$757K 0.05% 394
2024
Q4
$25.8M Buy
64,120
+693
+1% +$321K 0.04% 447
2024
Q3
$29.5M Sell
63,427
-22,148
-26% -$10.6M 0.04% 402
2024
Q2
$40.1M Buy
85,575
+6,368
+8% +$2.76M 0.06% 292
2024
Q1
$33.1M Buy
79,207
+4,662
+6% +$1.97M 0.06% 335
2023
Q4
$30.3M Buy
74,545
+5,598
+8% +$2.07M 0.06% 324
2023
Q3
$24M Sell
68,947
-588
-0.8% -$206K 0.05% 348
2023
Q2
$24.5M Buy
69,535
+2,225
+3% +$750K 0.05% 355
2023
Q1
$21.2K Buy
67,310
+1,015
+2% +$304K 0.04% 383
2022
Q4
$19.1M Buy
66,295
+2,992
+5% +$912K 0.05% 383
2022
Q3
$18.3M Sell
63,303
-7,743
-11% -$2.23M 0.05% 363
2022
Q2
$20M Buy
71,046
+206
+0.3% +$55.1K 0.05% 346
2022
Q1
$18.5M Buy
70,840
+5,437
+8% +$1.29M 0.04% 395
2021
Q4
$14.4M Sell
65,403
-9,388
-13% -$1.83M 0.03% 472
2021
Q3
$13.6M Buy
74,791
+9,820
+15% +$1.92M 0.03% 463
2021
Q2
$13.1M Buy
64,971
+12,489
+24% +$2.61M 0.03% 466
2021
Q1
$11.3M Sell
52,482
-6,957
-12% -$1.53M 0.03% 478
2020
Q4
$14M Buy
59,439
+13,889
+30% +$3.19M 0.04% 387
2020
Q3
$12.4M Buy
45,550
+5,930
+15% +$1.64M 0.04% 374
2020
Q2
$11.5M Buy
39,620
+19,673
+99% +$5.33M 0.04% 368
2020
Q1
$4.75M Buy
19,947
+2,393
+14% +$549K 0.02% 571
2019
Q4
$3.84M Buy
17,554
+2,339
+15% +$473K 0.01% 707
2019
Q3
$2.58M Sell
15,215
-735
-5% -$130K 0.01% 844
2019
Q2
$2.92M Sell
15,950
-369
-2% -$64.5K 0.01% 775
2019
Q1
$3M Buy
16,319
+721
+5% +$133K 0.01% 740
2018
Q4
$2.58M Buy
15,598
+150
+1% +$26K 0.01% 724
2018
Q3
$2.98M Buy
15,448
+4,990
+48% +$889K 0.01% 744
2018
Q2
$1.78M Buy
10,458
+591
+6% +$91.6K 0.01% 959
2018
Q1
$1.61M Buy
9,867
+603
+7% +$98.5K 0.01% 996
2017
Q4
$1.39M Sell
9,264
-268
-3% -$39.7K 0.01% 1044
2017
Q3
$1.45M Sell
9,532
-1,014
-10% -$153K 0.01% 984
2017
Q2
$1.36M Buy
10,546
+6
+0.1% +$722 0.01% 991
2017
Q1
$1.15M Buy
10,540
+1,481
+16% +$130K 0.01% 1048
2016
Q4
$667K Sell
9,059
-749
-8% -$60.9K ﹤0.01% 1250
2016
Q3
$855K Buy
9,808
+433
+5% +$40.9K 0.01% 1089
2016
Q2
$806K Buy
9,375
+2,376
+34% +$205K 0.01% 1090
2016
Q1
$556K Buy
6,999
+1,342
+24% +$121K 0.01% 1260
2015
Q4
$712K Buy
5,657
+399
+8% +$48.2K 0.01% 1102
2015
Q3
$548K Buy
5,258
+305
+6% +$39.2K 0.01% 1197
2015
Q2
$612K Sell
4,953
-1,052
-18% -$133K 0.01% 1219
2015
Q1
$708K Sell
6,005
-340
-5% -$40.7K 0.01% 1137
2014
Q4
$754K Buy
6,345
+1,208
+24% +$136K 0.01% 1044
2014
Q3
$577K Sell
5,137
-5,330
-51% -$507K 0.01% 1161
2014
Q2
$991K Buy
10,467
+2,522
+32% +$177K 0.01% 872
2014
Q1
$562K Buy
7,945
+1,841
+30% +$146K 0.01% 1104
2013
Q4
$454K Sell
6,104
-1,672
-22% -$116K 0.01% 1188
2013
Q3
$590K Buy
7,776
+523
+7% +$41.6K 0.01% 1007
2013
Q2
$581K Buy
+7,253
New +$534K 0.01% 952

Other funds holding VRTX

Commonwealth Equity Services's VRTX Position: Q1 2026 in Review

Commonwealth Equity Services increased its Vertex Pharmaceuticals (VRTX) stake by 1.5% in Q1 2026, buying an estimated $387K and bringing the position to 54,972 shares worth $24.5M. The position accounts for 0.03% of the portfolio, ranked #494.

Commonwealth Equity Services first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $40.1M in Q2 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Commonwealth Equity Services held 54,972 shares of Vertex Pharmaceuticals worth $24.5M as of Q1 2026.
  • Commonwealth Equity Services bought 829 Vertex Pharmaceuticals shares in Q1 2026, an estimated $387K.
  • Vertex Pharmaceuticals made up 0.03% of Commonwealth Equity Services's portfolio in Q1 2026, its #494 holding.
  • Commonwealth Equity Services first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Commonwealth Equity Services's Vertex Pharmaceuticals position peaked at $40.1M in Q2 2024.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.